Back to today’s briefing

Story perspectives

Shingles Vaccine Cuts Dementia Risk by 20% in Study

4/8/2025

24 3

Summary

Story summary

A groundbreaking study in Wales reveals that the shingles vaccine, Zostavax, can lower the risk of dementia diagnoses by 20% over seven years, especially among women. Analyzing data from over 280,000 adults aged 71-88, experts are calling on GPs to advocate for vaccination, while emphasizing the need for further research to establish a definitive connection. The newer Shingrix vaccine may also provide similar advantages.

1 of 1

Story summary

A groundbreaking study in Wales reveals that the shingles vaccine, Zostavax, can lower the risk of dementia diagnoses by 20% over seven years, especially among women. Analyzing data from over 280,000 adults aged 71-88, experts are calling on GPs to advocate for vaccination, while emphasizing the need for further research to establish a definitive connection. The newer Shingrix vaccine may also provide similar advantages.